Weight loss before infertility treatment in obese women not associated with improvement in healthy live birth rate
WEDNESDAY, Jan. 26, 2022 (HealthDay News) — Preconception weight loss prior to infertility therapy does not improve live birth or healthy live birth rates in women who were obese or overweight, according to a study published online Jan. 18 in PLOS Medicine.
Richard S. Legro, M.D., from Penn State College of Medicine in Hershey, and colleagues randomly assigned (1:1) 379 women with obesity (body mass index, ≥30 kg/m2) and unexplained infertility to one of two preconception lifestyle modification groups: increased physical activity and weight loss (target 7 percent) through meal replacements and medication (Orlistat; intensive group) compared to increased physical activity alone without weight loss (standard group). Interventions lasted 16 weeks and were followed by infertility therapy.
The researchers observed no significant differences in the incidence of healthy live births (15.2 percent in the standard group versus 12.2 percent in the intensive group; rate ratio 0.81; 95 percent confidence interval, 0.48 to 1.34; P = 0.40). Women randomly assigned to the intensive group had significant weight loss compared with those in the standard group (−6.6 versus −0.3). Improvements in metabolic health were observed in both groups, including a marked decrease in the incidence of metabolic syndrome (baseline to 16 weeks: standard, 53.6 to 49.4 percent; intensive, 52.8 to 32.2 percent). The intensive group had significantly more gastrointestinal side effects, and there was a higher rate of first-trimester pregnancy loss in the intensive group (33.3 versus 23.7 percent; rate ratio, 1.40; 95 percent confidence interval, 0.79 to 2.50), but the difference between the groups was not statistically significant.
“There is not strong evidence to recommend weight loss prior to conception in women who are obese with unexplained infertility,” the authors write.
Several authors disclosed financial ties to the pharmaceutical industry.
Low Levels of Placental Growth Factor in Pregnancy Linked to Subsequent ADHD in Offspring
Recommendations Issued for Use of Incretin-Based Meds in Pregnancy
2018 to 2025 Saw Sharp Rise in Postpartum GLP-1 Receptor Agonist Use
IBD Not Linked to Risk for Hypertensive Disorders of Pregnancy Overall
Pregnancy Complications Linked to Subsequent Risk for Cardiometabolic-Renal Conditions
Isometric Exercise Training Three Times a Week Preserves Cardiovascular Benefits
Serum 25(OH)D May Serve as Biomarker of Disease Activity in IBD
Maternal Vitamin D Status Linked to Preterm Delivery